Keftab, known generically as cephalexin, is a first-generation cephalosporin antibiotic designed to combat a wide spectrum of bacterial infections. It operates by inhibiting bacterial cell wall synthesis, leading to the eradication of susceptible pathogens. Clinically trusted for decades, Keftab is prescribed for respiratory, skin, urinary tract, and bone infections, among others. Its reliable pharmacokinetic profile ensures consistent bioavailability and tissue penetration, making it a frontline choice for physicians seeking a balance of efficacy and safety. This product card provides a detailed, evidence-based overview for healthcare professionals and informed patients.

Features

• Active ingredient: Cephalexin (as monohydrate)
• Available in 250 mg, 500 mg, and 750 mg oral tablets
• Belongs to the first-generation cephalosporin class
• Exhibits bactericidal activity against Gram-positive and some Gram-negative bacteria
• Standard packaging: 30, 60, or 90 tablets per bottle
• Requires prescription-only dispensing
• Manufactured under strict pharmaceutical compliance (cGMP)
• Shelf-stable under recommended storage conditions

Benefits

• Rapid onset of action with peak serum concentrations within one hour post-administration
• High clinical cure rates for common outpatient infections such as cellulitis and streptococcal pharyngitis
• Well-established safety profile with extensive post-marketing surveillance data
• Convenient twice-daily or four-times-daily dosing supports adherence
• Cost-effective compared to many newer broad-spectrum alternatives
• Low incidence of severe adverse effects when used as directed

Common use

Keftab (cephalexin) is indicated for the treatment of infections caused by susceptible strains of microorganisms, including respiratory tract infections such as bronchitis and pneumonia caused by Streptococcus pneumoniae and other streptococci; skin and soft tissue infections caused by staphylococci and streptococci; bone infections caused by Staphylococcus aureus and Proteus mirabilis; genitourinary tract infections, including acute prostatitis caused by Escherichia coli and Klebsiella pneumoniae; and otitis media caused by group A beta-hemolytic streptococci, pneumococci, and staphylococci. It may also be used for surgical prophylaxis in certain procedures.

Dosage and direction

The dosage of Keftab should be adjusted according to the infection’s severity, the patient’s renal function, and susceptibility of the causative organisms. For most infections in adults, the usual dose is 250 mg every 6 hours, or 500 mg every 12 hours. For more severe infections, doses may be increased to 500 mg every 6 hours or 1 g every 12 hours. In children, the recommended total daily dose is 25 to 50 mg/kg divided into two or four equal doses. For otitis media, doses of 75 to 100 mg/kg per day in divided doses are recommended. Keftab may be taken with or without food; administration with food may minimize gastrointestinal upset. Dosage should be reduced in patients with impaired renal function (creatinine clearance <50 mL/min). Complete the full prescribed course even if symptoms improve earlier.

Precautions

Before prescribing Keftab, obtain a detailed patient history regarding hypersensitivity reactions to cephalosporins, penicillins, or other drugs. Use with caution in patients with a history of gastrointestinal disease, particularly colitis, as antibiotic use can cause pseudomembranous colitis. Monitor renal function periodically during therapy in patients with pre-existing renal impairment. Prolonged use may result in overgrowth of nonsusceptible organisms; if superinfection occurs, take appropriate measures. Keftab should be used during pregnancy only if clearly needed and after weighing potential benefits against risks. It is excreted in human milk; caution is advised when administering to nursing women.

Contraindications

Keftab is contraindicated in patients with known hypersensitivity to cephalexin or any component of the formulation, or in those with a history of anaphylactic reactions to cephalosporins. Cross-hypersensitivity among beta-lactam antibiotics may occur; do not use in patients with immediate-type hypersensitivity reactions to penicillins.

Possible side effect

Common adverse reactions include diarrhea (occurring in up to 5% of patients), nausea, vomiting, dyspepsia, and abdominal pain. Less frequently reported side effects include dizziness, fatigue, headache, and reversible interstitial nephritis. Skin reactions such as rash, urticaria, and pruritus may occur. Rare but serious side effects include Clostridioides difficile-associated diarrhea, Stevens-Johnson syndrome, toxic epidermal necrolysis, eosinophilia, neutropenia, and hemolytic anemia. Discontinue use if severe hypersensitivity reactions or bloody diarrhea occurs.

Drug interaction

Probenecid may decrease renal tubular secretion of cephalexin, resulting in increased and prolonged blood levels. Concomitant use of bacteriostatic antibiotics may interfere with the bactericidal action of cephalexin. Use with caution alongside nephrotoxic drugs (e.g., aminoglycosides, potent diuretics) as this may increase the risk of renal toxicity. Cephalexin may cause false-positive reactions for glucose in the urine with Benedict’s or Fehling’s solutions and with Clinitest® tablets.

Missed dose

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next dose, skip the missed dose and resume the usual dosing schedule. Do not double the dose to make up for a missed one, as this may increase the risk of adverse effects.

Overdose

Symptoms of overdose may include nausea, vomiting, epigastric distress, diarrhea, and hematuria. In case of suspected overdose, discontinue the medication, treat symptomatically, and provide supportive care. Hemodialysis may aid in removing cephalexin from the body. Contact a poison control center or seek emergency medical attention immediately.

Storage

Store Keftab tablets at controlled room temperature, 20° to 25°C (68° to 77°F), with excursions permitted between 15° and 30°C (59° and 86°F). Keep the container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or changing your treatment plan. The efficacy and safety profile described are based on clinical studies and post-marketing experience; individual patient responses may vary. The manufacturer is not liable for misuse or incorrect interpretation of this data.

Reviews

Clinical studies and post-marketing surveillance consistently report high satisfaction rates among healthcare providers regarding Keftab’s efficacy in treating susceptible bacterial infections. In a meta-analysis of outpatient antibiotic therapy, cephalexin demonstrated a clinical success rate of over 85% for uncomplicated skin and soft tissue infections. Patients often note rapid symptom improvement, though some report mild gastrointestinal discomfort. Overall, it remains a widely trusted option within its spectrum of activity.